Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

"SKY-0515 provides exciting potential for Huntington's disease patients and leads a growing pipeline of RNA-targeting therapies developed by our SKYSTAR® platform," said Bill Haney, CEO and Co-Founder of Skyhawk Therapeutics. "Huntington's patients presently have few therapeutic options and none that reverse or slow disease progression. SKY-0515 has demonstrated strong activity in our preclinical models which we believe will translate to patient benefit." "SKY-0515 provides exciting potential...

"SKY-0515 provides exciting potential for Huntington's disease patients and leads a growing pipeline of RNA-targeting therapies developed by our SKYSTAR^® platform," said Bill Haney, CEO and Co-Founder of Skyhawk Therapeutics. "Huntington's patients presently have few therapeutic options and none that reverse or slow disease progression. SKY-0515 has demonstrated strong activity in our preclinical models which we believe will translate to patient benefit."

There are approximately 30,000 symptomatic Huntington's disease patients in the US alone and many more that are pre-symptomatic. There are currently no approved drugs that reverse or slow disease progression for Huntington's patients. SKY-0515 is a small molecule which directly targets HTT RNA, is dosed orally and offers brain penetration and distribution in peripheral tissues which may provide important benefits to patients. It is the first Skyhawk-developed drug to enter clinical trials.

Skyhawk Therapeutics' SKY-0515 Phase 1 clinical trial is a first-in-human, multi-part, randomized, double-blind, single and multiple ascending dose study designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of SKY-0515 monotherapy in healthy volunteers and, subsequently, Huntington's patients. Additional information about the trial can be found at: Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au).

About SKY-0515
Skyhawk Therapeutics is developing a small molecule RNA splicing modifier for potential treatment of Huntington's disease as part of the company's novel SKYSTAR^® platform. SKY-0515 is designed to reduce the production of the mutated huntingtin protein which results in disease progression. SKY-0515's predicted PK allows for daily, oral dosing, and the molecule is designed for brain penetration and distribution in peripheral tissue.

About Huntington's disease
Huntington's disease is a rare, inherited disease that causes the progressive degeneration of nerve cells in the brain. Huntington's disease has a wide impact on a person's functional abilities and usually results in movement, cognitive and psychiatric disorders. Huntington's disease symptoms can develop at any time, but they often first appear when people are in their 30s or 40s. If the condition develops before age 20, it's called juvenile Huntington's disease. When Huntington's develops early symptoms are somewhat different and the disease may progress faster. Medications are available to help manage the symptoms of Huntington's disease, but there is no cure for Huntington's disease, and currently no approved drugs that delay the disease onset or slow disease progression.

About Skyhawk
Skyhawk develops and commercializes therapies using its novel SKYSTAR^® platform, building small molecules that modify RNA expression to provide breakthrough treatments for patients. Skyhawk has productive collaborations across a broad range of disease areas, from neurodegenerative disease to oncology.

For more information visit:
www.skyhawktx.com
https://www.linkedin.com/company/skyhawk-therapeutics/ 
https://twitter.com/Skyhawk_Tx

SKYHAWK MEDIA CONTACT:
Maura McCarthymaura@skyhawktx.com

View original content:https://www.prnewswire.co.uk/news-releases/skyhawk-therapeutics-receives-hrec-approval-for-a-phase-1-study-of-its-sky-0515-rna-targeting-small-molecule-for-huntingtons-disease-301964052.html